Complex and differential glial responses in alzheimer´s disease and ageing

Current Alzheimer Research

Volumn 13, Issue 4, 2016, Pages 343-358

  Rodríguez, José J ^a,b   Butt, Arthur M ^c   Gardenal, Emanuela ^a,b   Parpura, Vladimir ^d,e   Verkhratsky, Alexei ^a,b,f  

^a BASQUE FOUNDATION FOR SCIENCE   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e University of Rijeka   (Croatia)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Alzheimer s disease; Astrocytes; Atrophy; Gliosis; Microglia; Myelin; Neurodegeneration; NG2 glia; Oligodendrocytes

Indexed keywords

MYELIN;

AGING; ALZHEIMER DISEASE; ASTROCYTE; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM FUNCTION; DEMENTIA; GLIA CELL; HOMEOSTASIS; HUMAN; MICROGLIA; OLIGODENDROCYTE PRECURSOR CELL; OLIGODENDROGLIA; PRIORITY JOURNAL; REVIEW; COMPLICATION; DEGENERATIVE DISEASE; GLIA; GLIOSIS; PATHOLOGY; PHYSIOLOGY;

AGING; ALZHEIMER DISEASE; GLIOSIS; HUMANS; NEURODEGENERATIVE DISEASES; NEUROGLIA;

EID: 84964026293     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666160229112911     Document Type: Review

References (174)

1. Virchow R. Gesammelte Abbildung zur wissenschaftlichen Medizin, Verlag von Meidinger Sohn & Comp (1856).
2. Virchow R. Die Cellularpathologie in ihrer Begründung auf physiologische and pathologische Gewebelehre. Zwanzig Vorlesungen gehalten während der Monate Februar, März und April 1858 im pathologischen Institut zu Berlin, August Hirschwald (1858).
3. Kettenmann H, Verkhratsky A. Neuroglia: the 150 years after. Trends Neurosci 31: 653-659 (2008).
4. Kölliker A. Handbuch der Gewebelehre des Menschen, Leipzig: Wilhelm Engelmann (1896).
5. Andriezen, WL. 1893. The neuroglia elements of the brain. Brit Med J 2: 227-230 (1889).
6. Lenhossek, M. (1893) Der feinere Bau des Nervensystems im Lichte neuester Forschung, Fischer’s Medicinische Buchhandlung H. Kornfield
7. Retzius G. (1894–1916) Biol Untersuchungen. Die Neuroglia des Gehirns beim Menschen und bei Saeugethieren, Verlag von Gustav Fischer
8. Golgi C. Opera Omnia. Hoepli (1903).
9. Rivers LE, Young KM, Rizzi M, Jamen F, Psachoulia K, Wade A, et al. PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform projection neurons in adult mice. Nat Neurosci 11: 1392-401 (2008).
10. Richardson WD, Young KM, Tripathi RB, McKenzie I. NG2-glia as multipotent neural stem cells: fact or fantasy? Neuron 70: 661-73 (2011).
11. Newman EA, Frambach DA, Odette LL. Control of extracellular potassium levels by retinal glial cell K+ siphoning. Science 225: 1174-1175 (1984).
12. Verkhratsky A, Kettenmann H. Calcium signalling in glial cells. Trends Neurosci 19: 346-52 (1996)
13. Nedergaard M, Ransom B, Goldman SA. New roles for astrocytes: redefining the functional aschitecture of the brain. Trends Neurosci 26: 523-30 (2003).
14. Zonta, M. Angulo, MC. Gobbo, S, Rosengarten B, Hossmann KA, Pozzen T, et al. Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nat Neurosci 6: 43-50 (2003).
15. Simard M, Nedergaard M, The neurobiology of glia in the context of water and ion homeostasis. Neuroscience 129: 877-896 (2004).
16. Kettenmann H. Ransom BR. (eds.) Neuroglia. 3rd Ed. Oxford, OUP, (2013).
17. Volterra A, Meldolesi J. Astrocytes, from brain glue to communication elements: the revolution continues. Nat Rev Neurosci 6: 626-40 (2005).
18. Magistretti PJ. Neuron-glia metabolic coupling and plasticity. J Exp Biol 209: 2304-2311 (2006).
19. Verkhratsky A. Glial calcium signalling in physiology and pathophysiology. Acta Pharmacol Sin 27: 773-780 (2006a).
20. Verkhratsky A. Patching the glia reveals the functional organisation of the brain. Pflugers Arch 453: 411-420 (2006b).
21. Verkhratsky A, Toescu EC. Neuronal-glial networks as substrate for CNS integration. J Cell Mol Med 10: 826-836 (2006).
22. Iadecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci 10: 1369-1376 (2007).
23. Verkhratsky A, Butt A. John Wiley & Sons, Glial Neurobiology: A textbook. Chichester: (2007).
24. Verkhratsky A, Kirchhoff F. NMDA Receptors in glia. Neuroscientist 13: 28-37 (2007).
25. Verkhratsky A. Neuronismo y reticulismo: neuronal-glial circuits unify the reticular and neuronal theories of brain organization. Acta Physiol (Oxf). 195: 111-122 (2009).
26. Verkhratsky A. Physiology of neuronal-glial networking. Neurochem Int 57: 332-343 (2010).
27. Verkhratsky A. Butt, A. Physiology and Pathophysiology of Neuroglia Chichester: Wiley, (2013).
28. Araque A, Parpura V, Sanzgiri RP, Haydon PG. Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci 22: 208-215 (1999).
29. Verkhratsky A, Nedergaard M. Astroglial cradle in the life of the synapse. Philos Trans R Soc Lond Ser B, Biol Sci 369: 20130595 (2014).
30. Rodríguez JJ, Matute C, Verkhratsky A. Neuroglia in Alzheimer’s Disease. In: Scemes E, Spray D, Eds. Astrocytes: Wiring the brain. USA: CRC Press pp. 311-338 (2012).
31. Verkhratsky A, Parpura V, Rodríguez JJ, Eds. Pathological potential of neuroglia: Possible new targets for medical intervention. In: Neurodegeneration and neuroglia: Emphasis on astroglia in Alzheimer’s disease. USA: Springer pp. 265-291 (2014).
32. Verkhratsky A, Marutle A, Rodríguez-Arellano JJ, Nordberg A. Glial asthenia and functional paralysis: A new perspective on neurodegeneration and Alzheimer’s disease. Neuroscientist (2014); [Epub ahead of print].
33. Nedergaard M, Verkhratsky A. Artifact versus reality -How astrocytes contribute to synaptic events? Glia 60: 1013-23 (2012).
34. Rodriguez JJ, Verkhratsky A. Neuroglial roots of neurodegenerative diseases? Mol Neurobiol 43: 87-96 (2011).
35. Oberheim NA, Takano T, Han X, He W, Lin JH, Wang F, et al. Uniquely hominid features of adult human astrocytes. J Neurosci 29: 3276-87 (2009).
36. Toledano A, Álvarez MI, Toledano-Díaz A, Merino JJ, Rodríguez JJ. Brain local and regional neuroglial alterations in Alzheimer´s Disease: cell types, responses and implications. Curr Alzheimer Res 13(4): 321-342 (2016).
37. Pekny M, Nilsson M. Astrocyte activation and reactive gliosis. Glia 50: 427-434 (2005).
38. Li L, Lundkvist A, Andersson D, Wilhelmsson U, Nagai N, Pardo AC, et al. Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab 28: 468-481 (2008).
39. Koeppen AH. Wallerian degeneration: history and clinical significance. J Neurol Sci 220: 115-117 (2004).
40. Vargas ME, Barres BA. Why is Wallerian degeneration in the CNS so slow? Annu Rev Neurosci 30: 153-179 (2007).
41. Guo F, Maeda Y, Ma J, Delgado M, Sohn J, Miers L, et al. Macroglial plasticity and the origins of reactive astroglia in experimental autoimmune encephalomyelitis. J Neurosci 31: 11914-28 (2011).
42. Vanzuli I, Rivera A, Arellano JJ, Butt A. Decreased regenerative capacity of oligodendrocyte progenitor cells (NG2-glia) in the ageing brain: a vicious cycle of synaptic dysfunction, myelin loss and neuronal disruption? Curr Alzheimer Res 13 (2016).
43. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10: 1387-1394 (2007).
44. Rodríguez JJ, Witton J, Olabarria M, Noristani HN, Verkhratsky A. Increase in the density of resting microglia precedes neuritic plaques formation and microglial activation in a transgenic model of Alzheimer’s disease. Cell Death Dis 1: e1 (2010).
45. Rodríguez JJ, Noristani HN, Hilditch T, Olabarria M, Yeh CY, Witton, J, et al. Increased densities of resting and activated microglia in the dentate gyrus follow senile plaque formation in the CA1 subfield of the hippocampus in the triple transgenic model of Alzheimer’s disease. Neurosci Lett 552: 129-34 (2013).
46. Rodríguez JJ, Noristani HN, Verkhratsky A. Microglial response to Alzheimer’s disease is differentially modulated by voluntary wheel running and enriched environments. Brain Struct Funct 220: 941-953 (2015).
47. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev 91: 461-553 (2011).
48. Giaume C, Kirchhoff F, Matute C, Reichenbach A, Verkhratsky A. Glia: the fulcrum of brain diseases. Cell Death Differ 14: 1324-1335 (2007).
49. Halassa MM, Fellin T, Haydon PG. The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med 13: 54-63 (2007).
50. Rossi D, Volterra A. Astrocytic dysfunction: Insights on the role in neurodegeneration. Brain Res Bull 80: 224-232 (2009).
51. Heneka MT, Rodriguez JJ, Verkhratsky A. Neuroglia in neurodegeneration. Brain Res Rev 63: 189-211 (2010).
52. Nedergaard M, Dirnagl U. Role of glial cells in cerebral ischemia. Glia 50: 281-286 (2005).
53. Nedergaard M, Rodriguez JJ, Verkhratsky, A. Glial calcium and diseases of the nervous system. Cell Calcium 47: 140-149 (2010).
54. Verkhratsky A, Sofroniew MV, Messing A, deLanerolle NC, Rempe D, Rodríguez JJ, et al. Neurological diseases as primary gliopathies: a reassessment of neurocentrism. ASN Neuro 4(3) (2012).
55. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 45: 1085-1098 (1999).
56. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42: 165-179 (2002).
57. Tian GF, Azmi H, Takano T, Xu Q, Peng W, Lin, J, et al. An astrocytic basis of epilepsy. Nat Med 11: 973-981 (2005).
58. Jabs R, Seifert G. Steinhauser, C. Astrocytic function and its alteration in the epileptic brain. Epilepsia 49(2): 3-12 (2008).
59. Fields RD. White matter in learning, cognition and psychiatric disorders. Trends Neurosci 31: 361-370 (2008).
60. Matute C, Alberdi E, Domercq M, Sanchez-Gomez MV, Perez-Samartin A, Rodriguez-Antiguedad A, et al. Excitotoxic damage to white matter. J Anat 210: 693-702 (2007).
61. Matute C. P2X7 receptors in oligodendrocytes: a novel target for neuroprotection. Mol Neurobiol 38: 123-128 (2008).
62. Antel J, Arnold D. Multiple sclerosis. In: Kettenmann H, Ransom B, (Eds.) Neuroglia. Oxford: Oxford University Press, pp. 489-500 (2005).
63. Ercolini AM, Miller SD. Mechanisms of immunopathology in murine models of central nervous system demyelinating disease. J Immunol 176: 3293-3298 (2006).
64. Jessen KR, Mirsky R. Negative regulation of myelination: relevance for development, injury, and demyelinating disease. Glia 56: 1552-1565 (2008).
65. van der Valk P, Amor S. Preactive lesions in multiple sclerosis. Curr Opin Neurol 22: 207-213 (2009).
66. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27: 119-145 (2009).
67. Rossi D, Brambilla L, Valori CF, Roncoroni C, Crugnola A, Yokota, T. et al. Focal degeneration of astrocytes in amyotrophic lateral sclerosis. Cell Death Differ 15: 1691-1700 (2008).
68. McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26: 459-470 (2002).
69. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 11: 251-253 (2008).
70. Korsakoff SS, Корсаков СС. psychosis polineuritica, s. cerebropathia psychica toxaemica. English translation: Korsakoff, S. S. Psychic disorder in conjunction with multiple neuritis, Translated from Russian by Victor, M. and Yakovlev, Neurology 5: 394-406. (1955).
71. Wernicke C. Lehrbuch der Gehirnkrankheiten für Aerzte und Studirende. Theodor Fischer, Kassel und Berlin (1881-1883).
72. Hazell AS. Astrocytes are a major target in thiamine deficiency and Wernicke’s encephalopathy. Neurochem Int 55: 129-135 (2009).
73. Hazell AS, Sheedy D, Oanea R, Aghourian M, Sun, S. Jung JY, et al. Loss of astrocytic glutamate transporters in Wernicke encephalopathy. Glia 58: 148-156 (2009).
74. Behrens PF, Franz P, Woodman B, Lindenberg KS. Landwehrmeyer, GB. Impaired glutamate transport and glutamateglutamine cycling: downstream effects of theHuntington mutation. Brain 125: 1908-22 (2002).
75. Lee W, Reyes RC, Gottipati MK, Lewis K, Lesort M, Parpura V, et al. Enhanced Ca(2+)-dependent glutamate release from astrocytes of the BACHD Huntington’s disease mouse model. Neurobiol Dis 58: 192-9 (2013).
76. Mena MA, Casarejos MJ, Carazo A, Paino CL, Garcia de Yebenes, J. Glia conditioned medium protects fetal rat midbrain neurones in culture from L-DOPA toxicity. Neuroreport 7: 441-445 (1996).
77. Mena MA, de Bernardo S, Casarejos MJ, Canals S, Rodriguez-Martin, E. The role of astroglia on the survival of dopamine neurons. Mol Neurobiol 25: 245-263 (2002).
78. Mena MA, Garcia de Yebenes J. Glial cells as players in parkinsonism: the "good," the "bad," and the "mysterious" glia. Neuroscientist 14: 544-560 (2008).
79. Brenner M, Johnson AB, Boespflug-Tanguy O, Rodriguez D, Goldman JE. Messing, A. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet 27: 117-120 (2001).
80. Brenner M, Goldman JE, Quinlan RA, Messing A. Alexander disease: a genetic disorder of astrocytes. In: Parpura, V. Haydon, PG. Eds.; Astrocytes in (Patho)Physiology of the Nervous System. Springer, New York: pp. 591-648 (2009).
81. Broe M, Kril J, Halliday GM. Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. Brain 127: 2214-2220 (2004)
82. Kersaitis C, Halliday GM, Kril JJ. Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. Acta Neuropathol 108: 515-523 (2004).
83. Potts R, Leech RW. Thalamic dementia: an example of primary astroglial dystrophy of Seitelberger. Clin Neuropathol 24: 271-275 (2005).
84. Kaul, M. Garden, GA. Lipton, SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410: 988-994 (2001).
85. Vanzani MC, Iacono RF, Caccuri RL, Troncoso AR, Berria MI. Regional differences in astrocyte activation in HIV-associated dementia. Medicina (B Aires) 66: 108-112 (2006).
86. Thompson KA, McArthur JC. Wesselingh, SL. Correlation between neurological progression and astrocyte apoptosis in HIVassociated dementia. Ann Neurol 49: 745-752 (2001).
87. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr Psych-Gericht Med 64: 146-148 (1907).
88. Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, et al. Dynamics of gray matter loss in Alzheimer’s disease. J Neurosci 23: 994-1005 (2003).
89. Thompson PM, Hayashi KM, Dutton RA, Chiang MC, Leow AD, Sowell ER. et al. Tracking Alzheimer’s disease. Ann NY Acad Sci 1097: 183-214 (2007).
90. Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC. Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease. Neurobiol Aging 25: 663-674 (2004).
91. Rodriguez JJ, Olabarria M, Chvatal A, Verkhratsky A. Astroglia in dementia and Alzheimer’s disease. Cell Death Differ 16: 378-385 (2009).
92. Alzheimer A. Beiträge zur Kenntnis der pathologischen Neuroglia und ihrer Beziehungen zu den Abbauvorgängen im Nervengewebe. In: Nissl F, Alzheimer A, (Eds.) Histologische und histopathologische Arbeiten über die Grosshirnrinde mit besonderer Berücksichtigung der pathologischen Anatomie der Geisteskrankheiten. Jena: Gustav Fischer, pp. 401-562 (1910).
93. Rodríguez JJ, Jones VC, Tabuchi M, Allan SM, Knight EM, et al. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer’s disease. PLoSOne 3(8): e2935 (2008).
94. Rodríguez-Arellano JJ, Parpura V, Zorec R, Verkhratsky A. Astrocytes in physiological aging and Alzheimer’s disease. Neuroscience pii: S0306-4522(15) 00031-7 (2015).
95. Verkhratsky A, Zorec R, Rodríguez JJ, Parpura V. Astroglia dynamics in ageing and Alzheimer’s disease. Curr Opin Pharmacol 26: 74-79 (2016).
96. DeWitt DA, Perry G, Cohen M, Doller C, Silver J. Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer’s disease. Exp Neurol 149: 329-340 (1998).
97. Abramov AY, Canevari L, Duchen MR. Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J Neurosci 23: 5088-5095 (2003).
98. Abramov AY. Canevari L. Duchen MR. ß-Amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 24: 565-575 (2004).
99. Kuchibhotla KV, Lattarulo CR, Hyman BT, Bacskai BJ. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science 323: 1211-1215 (2009).
100. Matos M. Augusto E, Oliveira CR, Agostinho P. Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience 156: 898-910 (2008).
101. Hartlage-Rubsamen M, Zeitschel U, Apelt J, Gartner U, Franke H, Stahl T, et al. Astrocytic expression of the Alzheimer’s disease β-secretase (BACE1) is stimulus-dependent. Glia 41: 169-179 (2003).
102. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether J, et al. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APPV717I. transgenic mice. J Neuroinflam 2: 22 (2005).
103. Nagele RG, D’Andrea MR, Lee H, 42 and give rise toβVenkataraman V, Wang HY. Astrocytes accumulate A astrocytic amyloid plaques in Alzheimer disease brains. Brain Res 971: 197-209 (2003).
104. Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 9(4): 453-457 (2003).
105. Olabarria M, Noristani HN, Verkhratsky A, Rodriguez JJ. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer’s disease. Glia 58: 831-838 (2010).
106. Olabarria M, Noristani HN, Verkhratsky A, Rodriguez JJ. Agedependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer’s disease mouse model: mechanism for deficient glutamatergic transmission? Mol Neurodegener 6: 55 (2011).
107. Yeh CY, Vadhwana B, Verkhratsky A, Rodriguez JJ. Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer’s disease. ASN Neuro 3: 271-279 (2011).
108. Kulijewicz-Nawrot M, Verkhratsky A, Chvatal A, Sykova E, Rodriguez JJ. Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer’s disease. J Anatomy 221: 252-262 (2012).
109. Kulijewicz-Nawrot M, Syková E, Chvátal A, Verkhratsky A, Rodríguez JJ. Astrocytes and glutamate homoeostasis in Alzheimer’s disease: a decrease in glutamine synthetase, but not in glutamate transporter-1, in the prefrontal cortex. ASN Neuro 5: 273-82 (2013)
110. Yeh CY, Verkhratsky A, Terzieva S, Rodríguez, JJ. Glutamine synthetase in astrocytes from entorhinal cortex of the triple transgenic animal model of Alzheimer’s disease is not affected by pathological progression. Biogerontology 14: 777-87 (2013).
111. Beauquis J, Pavía P, Pomilio C, Vinuesa A, Podlutskaya N, Galvan V, et al. Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer’s disease. Exp Neurol 239: 28-37 (2013).
112. Rodríguez JJ, Terzieva S, Olabarria M, Lanza RG, Verkhratsky A. Enriched environment and physical activity reverse astrogliodegeneration in the hippocampus of AD transgenic mice. Cell Death Dis 4(6): e678 (2013).
113. Toescu EC, Verkhratsky A. Landfield, PW. Ca2+ regulation and gene expression in normal brain aging. Trends Neurosci 27: 614-620(2004).
114. Burke SN, Barnes CA. Neural plasticity in the ageing brain. Nat Rev Neurosci 7: 30-40 (2006).
115. Fabricius K, Jacobsen JS, Pakkenberg B. Effect of age on neocortical brain cells in 90+ year old human females — a cell counting study. Neurobiol Aging 34: 91-99 (2013).
116. Pelvig DP, Pakkenberg H, Stark AK, Pakkenberg B. Neocortical glial cell numbers in human brains. Neurobiol Aging 29: 1754-1762 (2008).
117. Diniz DG, Foro CA, Rego CM, Gloria DA, de Oliveira FR, Paes JM, et al. Environmental impoverishment and aging alter object recognition, spatial learning, and dentate gyrus astrocytes. Eur J Neurosci 32: 509-519 (2010).
118. Cerbai F, Lana D, Nosi D, Petkova-Kirova P, Zecchi S, Brothers HM, et al. The neuron-astrocyte-microglia triad in normal brain ageing and in a model of neuroinflammation in the rat hippocampus. PLoS One 7: e45250 (2012).
119. Rodriguez JJ, Yeh CY, Terzieva S, Olabarria M, Kulijewicz-Nawrot M, Verkhratsky A. Complex and region-specific changes in astroglial markers in the aging brain. Neurobiol Aging 35: 15-23 (2014).
120. Grosche A, Grosche J, Tackenberg M, Scheller D, Gerstner G, Gumprecht A, et al. Versatile and simple approach to determine astrocyte territories in mouse neocortex and hippocampus. PLoS One 8: e69143 (2013).
121. Sampedro-Piquero P, De Bartolo P, Petrosini L, Zancada-Menendez C, Arias JL, Begega A. Astrocytic plasticity as a possible mediator of the cognitive improvements after environmental enrichment in aged rats. Neurobiol Learn Mem 114: 16-25 (2014).
122. Lalo U, Palygin O, North RA, Verkhratsky A, Pankratov, Y. Agedependent remodelling of ionotropic signalling in cortical astroglia. Aging Cell 10: 392-402 (2011).
123. Kress BT, Iliff JJ, Xia M, Wang M, Wei H, Zeppenfeld D, et al. Impairment of paravascular clearance pathways in the aging brain. Ann Neurol 76: 845-861 (2014).
124. Salminen A, Ojala J, Kaarniranta K, Haapasalo A, Hiltunen M, Soininen H. Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype. Eur J Neurosci 34: 3-11 (2011).
125. Matute C. Calcium dyshomeostasis in white matter pathology. Cell Calcium 47: 150-157 (2010).
126. Bartzokis G. Alzheimer’s disease as homeostatic responses to agerelated myelin breakdown. Neurobiol Aging 32: 1341-1371 (2009).
127. Shields SA, Gilson JM, Blakemore WF, Franklin RJ. Remyelination occurs as extensively but more slowly in old rats compared to young rats following gliotoxin-induced CNS demyelination. Glia 28: 77-83 (1999).
128. Franklin RJ. Why does remyelination fail in multiple sclerosis? Nature reviews. Neuroscience 3(9): 705-714 (2002).
129. Sim FJ, Zhao C, Penderis J, Franklin RJ. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci 22: 2451-2459 (2002).
130. Shen S, Sandoval J, Swiss VA, Li J, Dupree J, Franklin RJ, Casaccia-Bonnefil P. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat Neurosci 11: 1024-1034 (2008)
131. Salter MG, Fern R. NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 438: 1167-1171 (2005).
132. Butt AM, Duncan A, Hornby MF, Kirvell SL, Hunter A, Levine JM, et al. Cells expressing the NG2 antigen contact nodes of Ranvier in adult CNS white matter. Glia 26: 84-91 (1999).
133. Hamilton N, Vayro S, Wigley R, Butt AM. Axons and astrocytes release ATP and glutamate to evoke calcium signals in NG2-glia. Glia 58: 66-79 (2010).
134. Kukley M, Capetillo-Zarate E, Dietrich D. Vesicular glutamate release from axons in white matter. Nat Neurosci 10: 311-320 (2007).
135. Wake H, Lee PR, Fields RD. Control of local protein synthesis and initial events in myelination by action potentials. Science 333: 1647-1651 (2011).
136. Gibson EM, Purger D, Mount CW, Goldstein AK, Lin GL, Wood LS, et al. Neuronal activity promotes oligodendrogenesis and adaptive myelination in the mammalian brain. Science 344: 1252304 (2014).
137. Gallo V, Zhou JM, McBain CJ, Wright P, Knutson PL, Armstrong RC. Oligodendrocyte progenitor cell proliferation and lineage progression are regulated by glutamate receptor-mediated K+ channel block. J Neurosci 16: 2659-2670 (1996).
138. Gudz TI, Komuro H, Macklin WB. Glutamate stimulates oligodendrocyte progenitor migration mediated via an alphav integrin/ myelin proteolipid protein complex. J Neurosci 26: 2458-2466 (2006).
139. Lundgaard I, Luzhynskaya A, Stockley JH, Wang Z, Evans KA, Swire M, et al. Neuregulin and BDNF induce a switch to NMDA receptor-dependent myelination by oligodendrocytes. PLoS Biol 11: e1001743 (2014).
140. Pickel VM, Garzón M, Mengual E. Electron microscopic immunolabeling of transporters and receptors identifies transmitter-specific functional sites envisioned in Cajal’s neuron. Prog Brain Res 136: 145-55 (2002).
141. Stys PK. The axo-myelinic synapse. Trends Neurosci 34: 393-400 (2011).
142. Etxeberria A, Mangin JM, Aguirre A, Gallo V. Adult-born SVZ progenitors receive transient synapses during remyelination in corpus callosum. Nat Neurosci 13: 287-289 (2010).
143. Peters, A. Verderosa A, Sethares C. The neuroglial population in the primary visual cortex of the aging rhesus monkey. Glia 56: 1151-1161 (2008).
144. Psachoulia K, Jamen F, Young KM, Richardson WD. Cell cycle dynamics of NG2 cells in the postnatal and ageing brain. Neuron Glia Biol 5: 57-67 (2009).
145. Simon C, Gotz M, Dimou L. Progenitors in the adult cerebral cortex: cell cycle properties and regulation by physiological stimuli and injury. Glia 59: 869-381 (2011).
146. Bowley MP, Cabral H, Rosene DL, Peters A. Age changes in myelinated nerve fibers of the cingulate bundle and corpus callosum in the rhesus monkey. J Comp Neurol 518: 3046-3064 (2010).
147. Bartzokis G. Alzheimer’s disease as homeostatic responses to agerelated myelin breakdown. Neurobiol Aging 32: 1341-1371 (2009).
148. Brant-Zawadzki M, Fein G, Van Dyke C, Kiernan R, Davenport L, de Groot J. MR imaging of the aging brain: patchy white-matter lesions and dementia. AJNR Am J Neuroradiol 6: 675-682 (1985).
149. McLachlan DR, Wong L, Bergeron C, Baimbridge KG. Calmodulin and calbindin D28K in Alzheimer disease. Alzheimer Dis Assoc Disord 1: 171-179 (1987).
150. Larsson E, Passant U, Sundgren PC, Englund E, Brun A, Lindgren A, et al. Magnetic resonance imaging and histopathology in dementia, clinically of frontotemporal type. Dement Geriatr Cogn Disord 11: 123-134 (2000).
151. Yoshida M. Amyotrophic lateral sclerosis with dementia: the clinicopathological spectrum. Neuropathology 24: 87-102 (2004).
152. Steffens DC, Potter GG, McQuoid DR, MacFall JR, Payne ME, Burke JR, et al. Longitudinal magnetic resonance imaging vascular changes, apolipoprotein E genotype, and development of dementia in the neurocognitive outcomes of depression in the elderly study. Am J Geriatr Psychiatry 15: 839-849 (2007).
153. Staekenborg SS, Koedam EL, Henneman WJ, Stokman P, Barkhof F, Scheltens P, et al. Progression of mild cognitive impairment to dementia: contribution of cerebrovascular disease compared with medial temporal lobe atrophy. Stroke 40: 1269-1274 (2009).
154. Bronge L. Magnetic resonance imaging in dementia. A study of brain white matter changes. Acta Radiol Suppl (428): 1-32 (2002).
155. Brown WR, Moody DM, Thore CR, Challa VR. Cerebrovascular pathology in Alzheimer’s disease and leukoaraiosis. Ann N Y Acad Sci 903: 39-45 (2000).
156. Mattson MP, Chan SL. Neuronal and glial calcium signaling in Alzheimer’s disease. Cell Calcium 34: 385-397 (2003).
157. Xu J, Chen S, Ahmed SH, Chen H, Ku G, Goldberg MP, Hsu CY. Amyloid-beta peptides are cytotoxic to oligodendrocytes. J Neurosci 21: RC118 (2001).
158. Pak K, Chan SL, Mattson MP. Presenilin-1 mutation sensitizes oligodendrocytes to glutamate and amyloid toxicities, and exacerbates white matter damage and memory impairment in mice. Neuromol Med 3: 53-64 (2003).
159. Jantaratnotai N, Ryu JK, Kim SU, McLarnon JG. Amyloid beta peptide-induced corpus callosum damage and glial activation in vivo. Neuroreport 14: 1429-1433 (2003).
160. Desai MK, Sudol KL, Janelsins MC, Mastrangelo MA, Frazer ME, Bowers WJ. Triple-transgenic Alzheimer’s disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia 57: 54-65 (2009).
161. Burns JM, Church JA, Johnson DK, Xiong C, Marcus D, Fotenos AF, et al. White matter lesions are prevalent but differentially related with cognition in aging and early Alzheimer disease. Arch Neurol 62: 1870-1876 (2005).
162. Nielsen HM, Ek D, Avdic U, Orbjörn C, Hansson O, Netherlands BB, et al. NG2 cells, a new trail for Alzheimer’s disease mechanisms? Acta Neuropathol Commun 1: 7 (2013).
163. McGeer EG, McGeer PL. Brain inflammation in Alzheimer disease and the therapeutic implications. Curr Pharm Des 5: 821-836 (1999).
164. Heneka MT, O’Banion MK. Inflammatory processes in Alzheimer’s disease. J Neuroimmunol 184: 69-91 (2007).
165. Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, et al. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152: 307-317 (1998).
166. Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, et al. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci 28: 4283-4292 (2008).
167. Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 388: 878-881 (1997).
168. Schubert P, Morino T, Miyazaki H, Ogata T, Nakamura Y, Marchini C, et al. Cascading glia reactions: a common pathomechanism and its differentiated control by cyclic nucleotide signaling. Ann NY Acad Sci 903: 24-33 (2000).
169. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease. Nature 451: 720-724 (2008).
170. Sanz JM, Chiozzi P, Ferrari D, Colaianna M, Idzko M, Falzoni S, et al. Activation of microglia by amyloid b requires P2X7 receptor expression. J Immunol 182: 4378-4385 (2009).
171. Lotz M, Ebert S, Esselmann H, Iliev AI, Prinz M, Wiazewicz N, et al. Amyloid b peptide 1-40 enhances the action of Toll-like receptor-2 and -4 agonists but antagonizes Toll-like receptor-9-induced inflammation in primary mouse microglial cell cultures. J Neurochem 94: 289-298 (2005).
172. Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV. Toll-like receptors in neurodegeneration. Brain Res Rev 59: 278-292 (2009).
173. Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, et al. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer’s disease. Cell Physiol Biochem 20: 947-956 (2007).
174. Ohm TG. The dentate gyrus in Alzheimer’s disease. Prog Brain Res 163: 723-740 (2007).